CRMH-RP3 Homepage

 ♢ Home  ♢ Leadership  ♢ Drug Discovery  ♢ Events and Publications  ♢ Photo Gallery  ♢ Contact Us

Four Pillars of Drug Discovery

RP3 has established three of the four pillars of drug discovery: People, Platform and Pipeline. Current goal of RP3 is the Translation of its drugs in human clinical trials.

Pillar I: People

image-20230910114849560

  • International team of drug discovery scientists
  • Successful talent recruitment in diversified disciplines by RP3 has been completed
  • Total staff is currently 65 (critical mass!)
  • Click here for a full list of RP3 members

Pillar II: Platform

image-20230910135827999

  • Each platform fully equipped and staffed
  • Allows RP3 to conduct drug development from target validation to IND candidate nomination
  • Compound Screening Platform
    • Semi-automated HTS center
    • 20 screening assays available
    • 96 and 384 plate formats available
    • Internal compound library being built
  • Analytical Chemistry Platform
    • Full chemical analysis of compounds
    • NMR, MS, LC-MS, LC-MS/MS, HPLC
  • Pharmacology Platform
    • Pharmacokinetics of drugs in rodents
    • In vivo behavioral & musculoskeletal disease models in mice and rats established
  • Medicinal Chemistry Platform
    • Over 500 new chemical entities synthesized
    • Deuterium-substitution based chemistry
    • Peptide based chemistry

Pillar III: Pipeline

image-20230910135453970

  • Drugs for cognitive regeneration
    • Preserving the brain extracellular matrix using small molecule drugs as a strategy for blocking neural degeneration
    • Development of GPCR agonists as a stratagem for curing tinnitus & amblyopia
    • Development of GPCR antagonists for alleviating epilepsy
    • In-vitro and in-vivo assay platforms for assessing drug efficacy for brain disorders
    • Mechanism-based studies on the role of orphan GPCRs in brain health
  • Drugs for muscle skeletal regeneration
    • Development of natural small molecules to promote osteoporotic fracture healing
    • Study the role of mesenchymal cells in cartilage repair
    • Development of enterotoxins as drugs to promote osteoporotic fracture healing

Pillar IV: Translation

RP3 is now engaged in clinical development of its lead drugs. Primary focus is RP3’s CNS portfolio:

image-20230910142308241

Innovative Pipeline of Drugs

Agent Target Drug Class Indication
3r1 GPCR Agonist Amblyopia
866 GPCR Agonist Tinnitus
JM-484 GPCR Antagonist Epilepsy
  • 3R1 is a novel small molecule agonist targeting a GPCR in the visual cortex of the brain for the treatment and cure for childhood and adult Amblyopia;
  • 866 is a new small molecule agonist against a GPCR in the audio cortex of the brain for the treatment and cure of Tinnitus;
  • JM-484 is a small molecule antagonist targeting a GPCR in the neocortex of the brain as a novel approach for treating Epilepsy

Developmental stages